Publications

March 2003
Article

Technological Development and Medical Productivity: The Diffusion of Angioplasty in New York State

By: David M. Cutler and Robert S. Huckman

A puzzling feature of many medical innovations is that they simultaneously appear to reduce unit costs and increase total costs. We consider this phenomenon by examining the diffusion of percutaneous transluminal coronary angioplasty (PTCA)—a treatment for coronary... View Details

Keywords: Innovation and Invention; Cost; Health Care and Treatment; Health Disorders; Performance Improvement; Product; New York (state, US)

February 2019 (Revised August 2019)
Case

KangaTech

By: Karim R. Lakhani, Patrick J. Ferguson, Sarah Fleischer, Jin Hyun Paik and Steven Randazzo

On a warm January afternoon in 2019, Steve Saunders, Dave Scerri, Carl Dilena, and Nick Haslam (see Exhibit 1 for biographies), co-founders of KangaTech, wrapped up the latest round of discussions about the future direction of their sports-technology start-up. Focused... View Details

Keywords: Startup; Technology Commercialization; Prototype; Business Startups; Technological Innovation; Sports; Health; Commercialization; Research and Development; Decision Making; Growth and Development Strategy; Health Industry; Health Industry; Health Industry; Australia

2010
Article

Estimating the Attributable Cost of Physician Burnout in the United States

By: Shasha Han, Tait D. Shanafelt, Christine A. Sinsky, Karim M. Awad, Liselotte N. Dyrbye, Lynne C. Fiscus, Mickey Trockel and Joel Goh

Background: Although physician burnout is associated with negative clinical and organizational outcomes, its economic costs are poorly understood. As a result, leaders in health care cannot properly assess the financial benefits of initiatives to remediate... View Details

Keywords: Physicians; Burnout; Health; Health Care and Treatment; Employees; Cost; Programs; Policy; Health Industry

Read Now

July 2005 (Revised December 2006)
Case

Japan: Deficits, Demography, and Deflation

By: Richard H.K. Vietor

By 2005, Japan's debt had risen to 163% of GDP. For more than a decade, the government had run huge deficits, trying unsuccessfully to stimulate economic growth. Interest rates, meanwhile, had been zero for years. But with slow growth and banks in crisis, nothing had... View Details

Keywords: Economy; Economic Growth; Demographics; Financial Condition; Inflation and Deflation; Banks and Banking; Borrowing and Debt; Macroeconomics; Policy; Government and Politics; Welfare; Health Care and Treatment; Japan

14 Mar 2017
First Look

First Look at New Research, March 14

https://www.hbs.edu/faculty/Pages/item.aspx?num=52405 forthcoming Critical Finance Review Inflation Bets or Deflation Hedges? The Changing Risks of Nominal Bonds By: Campbell, John Y., Adi Sunderam, and Luis M. Viceira Abstract—The... View Details

Keywords: Sean Silverthorne

14 Feb 2023
HBS Case

Is Sweden Still 'Sweden'? A Liberal Utopia Grapples with an Identity Crisis

Sweden has long seemed like a social-welfare capitalist dream come true, where companies and labor unions collaborate in harmony with government support. Swedish citizens are among the wealthiest in the world, and they enjoy publicly provided View Details

Keywords: by Lane Lambert

September 2022
Article

Find and Replace: R&D Investment Following the Erosion of Existing Products

By: Joshua L. Krieger, Xuelin Li and Richard T. Thakor

How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using FDA Public Health Advisories as idiosyncratic negative shocks to approved drugs, we first... View Details

Keywords: R＆D Investments; Drug Development; Product Shocks; M＆A; Biopharmaceutical Industry; FDA; System Shocks; Research and Development; Investment; Decision Making; Pharmaceutical Industry

Article

Motivated Inferences of Price and Quality in Healthcare Decisions

By: Emily Prinsloo, Kate Barasz and Peter A. Ubel

Policy makers have increasingly advocated for healthcare price transparency, whereby prices are made salient before services are rendered. While such policies may empower consumers, they also bring price to the forefront of healthcare choices as never before, with yet... View Details

Keywords: Healthcare; Price Transparency; Health Care and Treatment; Price; Quality; Perception; Consumer Behavior; Decisions; Insurance

Register to Read

July 2020
Article

Lessons from the Impact of Price Regulation on the Pricing of Anticancer Drugs in Germany

By: Victoria D. Lauenroth, Aaron S. Kesselheim, Ameet Sarpatwari and Ariel Dora Stern

Worldwide spending on prescription drugs has increased dramatically in recent years. Although this increase has been particularly pronounced in the U.S., it remains largely unaddressed there. In Europe, however, different approaches to regulating drug prices have been... View Details

Keywords: Pharmaceuticals; Prescription Drug Costs; Drug Pricing; Access To Care; Cost Reduction; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Cost Management; Germany

Read Now

Article

Asset Accumulation and Labor Force Participation of Disability Insurance Applicants

By: Pian Shu

This paper provides empirical evidence of the existence of forward-looking asset-accumulation behavior among disability-insurance applicants, previously examined only in the theoretical literature. Using panel data from the RAND Health and Retirement Study, I show that... View Details

Keywords: Disability Insurance; Asset Accumulation; Labor Force Participation; Assets; Behavior; Employment; Insurance; Insurance Industry; United States

05 Jun 2007
First Look

First Look: June 5, 2007

raised Audax Group's first fund, and are not able personally to finance the purchase, which would require approximately $30 million. They must decide whether to go through with the purchase, and how to View Details

Keywords: Martha Lagace

January 2008 (Revised May 2009)
Case

Restructuring at Delphi Corporation (A)

By: Stuart C. Gilson and Sarah L. Abbott

Delphi Corporation, operating under Chapter 11 bankruptcy protection, has filed a plan of reorganization with the court, under which a consortium of hedge funds led by Appaloosa Management will invest up to $2.6 billion in new equity. Also participating in the plan is... View Details

Keywords: Restructuring; Capital Structure; Private Equity; Insolvency and Bankruptcy; Investment Funds; Labor and Management Relations; Auto Industry; Service Industry

May 2022
Article

Strengthening Digital Infrastructure: A Policy Agenda for Free and Open Source Software

By: Frank Nagle

While there is little debate that digital forces are playing an increasingly crucial role in the economy, there is limited understanding of the importance of the digital infrastructure that underlies this role. Much of the discussion around digital infrastructure has... View Details

Keywords: Open Source; Applications and Software; Policy; Infrastructure; Open Source Distribution

Read Now

September 2019
Case

Dementia Discovery Fund

By: Richard G. Hamermesh, Kathy Giusti and Sarah Gulick

The case is set in March 2019, and tells the story of the founding of the Dementia Discovery Fund (DDF). The idea for the fund began in 2015, when then-Prime Minister David Cameron spoke about the importance of making breakthroughs in dementia research, and pledged... View Details

Keywords: Venture Capital; Investment Funds; Mission and Purpose; Recruitment; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Boston; Massachusetts; London; England

July 2020
Case

Mortgage Backed Securities and the Covid-19 Pandemic

By: Emil N. Siriwardane, Luis M. Viceira and Dean Xu

In April 2020, global financial markets were still reeling as the COVID-19 pandemic spread rapidly across the world. Global equity markets had initially fallen by 30% in response to the pandemic, and high-yield credit markets had dropped by nearly 20%. In contrast,... View Details

Keywords: COVID-19; Mortgage-backed Securities; Health Pandemics; Financial Markets; Assets; Resource Allocation; Financial Instruments; Decision Making

Summer 2021
Article

The Cost and Evolution of Quality at Cipla Ltd, 1935–2016

By: Muhammad H. Zaman and Tarun Khanna

This article examines the evolution of Indian pharmaceutical manufacturer Cipla towards producing drugs that met the quality standards of European and U.S. regulators. It employs new research in Cipla’s corporate archives, the Creating Emerging Markets database, and... View Details

Keywords: Cipla; Pharmaceuticals; Drug Quality; Generics; Quality; Standards; Information Technology; Cost; Organizational Culture; Business History; Pharmaceutical Industry; India